Prolonged digitoxin half-life in very elderly patients

Age and Ageing

Volumn 27, Issue 2, 1998, Pages 222-224

  Bøhmer, Thomas ^a   Røseth, Arne ^a  

^a AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Digitoxin; Digitoxin bis digitoxoside; Drug toxicity; Elderly; Heart failure

Indexed keywords

DIGITOXIN;

AGED; ARTICLE; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG INTOXICATION; HEART FAILURE; HUMAN; PRIORITY JOURNAL;

AGED, 80 AND OVER; AGING; CARDIOTONIC AGENTS; DIGITOXIN; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 0031970619     PISSN: 00020729     EISSN: None     Source Type: Journal    
DOI: 10.1093/ageing/27.2.222     Document Type: Article

References (16)

1. Kraus F, Rudolph C, Rudolph W. Effectivity of digitalis in patients with chronic heart failure and sinus rythm: an overview of randomised double-blind placebo-controlled studies. Herz 1993; 18: 95-117.
2. Smith TW. Digoxin in heart failure. N Engl J Med 1993; 329: 51-3.
3. Packer M, Gheorghiade M, Young JB, Constantini PJ, Adams KF, Cody RJ et al. for RADIANCE study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med 1993; 329: 1-7.
4. Dargie HJ, McMurray JJV. Diagnosis and management of heart failure. Br Med J 1994; 308: 321-8.
5. Hoffmann BF, Bigger JT Jr. Digitalis and allied cardiac glycosides. In: Goodman Gillman A, Rail TW, Nies AS, Taylor P eds. The Pharmacological Basis of Therapeutics, eighth edition. New York: Pergamon Press, 1990; 814-39.
6. Storstein O, Hansteen V, Hatle L, Hillestad L, Storstein L. Studies of digitalis XII. A prospective study of 649 patients on maintenance treatment with digitoxin. Am Heart J 1977; 93: 434-43.
7. Wagner JG. Appraisal of digoxin bioavailability and pharmacokinetics in relation to cardiac therapy. Am Heart J 1974; 88: 133-8.
8. Jeliffe RW. A mathematical analysis of digitalis kinetics in patients with normal and reduced renal function. Math Biosc 1967; 1: 305-25.
9. Kirch W, Ohnhaus EE, Dylewicz P, Pabst J, Storstein L. Bioavailability and elimination of digitoxin in patients with hepatorenal insufficiency. Am Heart J 1986; 111: 325-9.
10. Nokhodian A, Santos SR, Kirch W. Digitoxin and its metabolites in patients with liver cirrhosis. Eur J Drug Metab Pharmacokinet 1993; 18: 207-13.
11. Bussey HI, Hawkins DW, Gaspard JJ, Walsh RA. A comparative trial of digoxin and digitoxin in the treatment of congestive heart failure. Pharmacotherapy 1988; 8: 235-40.
12. Sawyer WT. The digitalis glycosides. In: Taylor WJ, Diers Caviness MH eds. A Textbook for the Clinical Application of Therapeutic Drug Monitoring. Irving, TX: Diagnostic Division, Abbott Laboratories, 1986; 83-96.
13. Donovan MA, Castleden CM, Pohl JEF, Kraft CA. The effect of age on digitoxin pharmacokinetics. Br J Clin Pharmacol 1981; 11: 401-2.
14. Eberhart DC, Gemzik B, Halvorsen MR, Parkinson A. Species differences in the toxicity and cytochrome p-450 III A-dependent metabolism of digitoxin. Mol Pharmacol 1991; 40: 859-67.
15. Mowe M, Bøhmer T, Kindt E. Reduced nutritional status in an elderly population (>70 y) is probable before disease and possibly contributed to the development of disease. Am J Clin Nutr 1994; 59: 317-24.
16. Brors O, Fremstad D, Poulsson C. The affinity of human serum albumin for 3H-digitoxin is dependant on albumin concentration. Pharmacol Toxicol 1993; 72: 310-3.